MedTrace Logo

Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia

NCT02896829 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2020-06-19

No results posted yet for this study

Summary

It's an observational study based on 98 patients included in the STIM trial to extend the monitoring of patients and to have molecular and clinical data, with long follow up. Are there late relapses? What has become patients who relapsed during STIM trial and restarted TKI (inhibitor tyrosine kinase) treatment?

Conditions

  • Chronic Myeloid Leukemia

Interventions

BEHAVIORAL

Interruption of the treatment by Imatinib

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-03
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02896829 on ClinicalTrials.gov